Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
04
2022
accepted:
07
03
2023
medline:
6
4
2023
entrez:
5
4
2023
pubmed:
6
4
2023
Statut:
epublish
Résumé
There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reaction testing was conducted on urine and rectal samples to detect Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT) every 6 months. Syphilis serology was conducted at month 0 and thereafter every 12 months. We calculated STI prevalence and the associated 95% confidence intervals until 24 months of follow-up. The trial enrolled 183 participants who identified as male or transgender female, and of homosexual or bisexual orientation. Of these, 173 had STI testing done at month 0, median age was 23 (IQR 20-25) years, with median 20.5 (IQR 17.5-24.8) months follow-up (FU). The clinical trial also enrolled and performed month 0 STI testing on 3389 female participants, median age 23 (IQR 21-27) years, median 24.8 (IQR 18.8-24.8) months FU and 1080 non-MSM males with a median age of 27 (IQR 24-31) years, median 24.8 (IQR 23-24.8) months FU. At month 0, CT prevalence was similar in MSM and females (26.0% vs 23.0%, p = 0.492) but was more prevalent in MSM compared to non-MSM males (26.0% vs 14.3%, p = 0.001). CT was the most prevalent STI among MSM at months 0 and 6 but declined from month 0 to month 6 (26.0% vs 17.1%, p = 0.023). In contrast, NG did not decline in MSM between months 0 and 6 (8.1% vs 7.1%, p = 0.680) nor did syphilis prevalence between months 0 and 12 (5.2% vs 3.8%, p = 0.588). Bacterial STI burden is higher in MSM compared to non-MSM males, and CT is the most prevalent bacterial STI amongst MSM. Preventive STI vaccines, especially against CT, may be helpful to develop.
Identifiants
pubmed: 37018240
doi: 10.1371/journal.pgph.0001782
pii: PGPH-D-22-00629
pmc: PMC10075439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001782Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068614
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069453
Pays : United States
Informations de copyright
Copyright: © 2023 Mashingaidze et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
MMWR Morb Mortal Wkly Rep. 2019 Apr 12;68(14):321-325
pubmed: 30973847
N Engl J Med. 2021 Mar 25;384(12):1089-1100
pubmed: 33761206
Vaccine. 2013 Apr 12;31(16):2089-96
pubmed: 23370155
J Int AIDS Soc. 2020 Oct;23 Suppl 6:e25594
pubmed: 33000886
PLoS One. 2018 Oct 15;13(10):e0205863
pubmed: 30321236
J Dtsch Dermatol Ges. 2017 Apr;15(4):421-428
pubmed: 28294529
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
Arch Virol. 2020 Nov;165(11):2439-2452
pubmed: 32797338
Int J Equity Health. 2016 Jan 22;15:16
pubmed: 26800682
Clin Infect Dis. 2018 Feb 10;66(5):735-742
pubmed: 29028966
Infect Dis Obstet Gynecol. 2016;2016:5758387
pubmed: 27366021
BMC Infect Dis. 2013 Nov 16;13:549
pubmed: 24238403
BMC Infect Dis. 2019 Aug 5;19(1):686
pubmed: 31382923
Int J STD AIDS. 2020 Feb;31(2):127-135
pubmed: 31992145
Annu Rev Sex Res. 2000;11:125-57
pubmed: 11351830
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S183-6
pubmed: 23764634
AIDS Behav. 2011 Jul;15(5):1026-32
pubmed: 19636698